Mallappallil Mary, Sasidharan Sandeep, Sabu Jacob, John Sabu
Internal Medicine and Nephrology, New York City (NYC) Health + Hospitals/Kings County Hospital Center, Brooklyn, USA.
Internal Medicine and Nephrology, State University of New York (SUNY) Downstate University of Health Sciences, Brooklyn, USA.
Cureus. 2024 Jul 16;16(7):e64663. doi: 10.7759/cureus.64663. eCollection 2024 Jul.
Diabetes mellitus (DM) is a common cause of chronic kidney disease (CKD), leading to the need for renal replacement therapy (RRT). RRT includes hemodialysis (HD), peritoneal dialysis (PD), kidney transplantation (KT), and medical management. As CKD advances, the management of DM may change as medication clearance, effectiveness, and side effects can be altered due to decreasing renal clearance. Medications like metformin that were safe to use early in CKD may build up toxic levels of metabolites in advanced CKD. Other medications, like sodium-glucose co-transporter 2 inhibitors, which work by excreting glucose in the urine, may not be able to work effectively in advanced CKD due to fewer working nephrons. Insulin breakdown may take longer, and both formulation and dosing may need to be changed to avoid hypoglycemia. While DM control contributes to CKD progression, effective DM control continues to be important even after patients have been placed on RRT. Patients on RRT are frequently taken care of by a team of providers, including the primary care physician, both in and outside the hospital. Non-nephrologists who are involved with the care of a patient treated with RRT need to be adept at managing DM in this population. This paper aims to outline the management of type 2 DM in advanced CKD.
糖尿病(DM)是慢性肾脏病(CKD)的常见病因,会导致需要进行肾脏替代治疗(RRT)。RRT包括血液透析(HD)、腹膜透析(PD)、肾移植(KT)和药物治疗。随着CKD的进展,DM的管理可能会发生变化,因为肾脏清除率降低会改变药物清除率、有效性和副作用。在CKD早期使用安全的药物,如二甲双胍,在晚期CKD中可能会积聚有毒水平的代谢产物。其他药物,如钠-葡萄糖协同转运蛋白2抑制剂,其作用是通过尿液排泄葡萄糖,在晚期CKD中由于有功能的肾单位减少可能无法有效发挥作用。胰岛素分解可能需要更长时间,并且可能需要改变剂型和剂量以避免低血糖。虽然控制DM会促进CKD进展,但即使患者已开始接受RRT,有效控制DM仍然很重要。接受RRT的患者通常由包括初级保健医生在内的一组医疗人员在医院内外进行护理。参与接受RRT治疗患者护理的非肾病科医生需要善于管理该人群的DM。本文旨在概述晚期CKD中2型DM的管理。